<DOC>
	<DOC>NCT01987960</DOC>
	<brief_summary>To evaluate the efficacy of brexpiprazole as adjunctive treatment to paroxetine (PAR) or sertraline (SER) on PTSD symptoms.</brief_summary>
	<brief_title>Brexpiprazole as an Adjunctive Treatment to Paroxetine or Sertraline in Adult Patients Suffering From Post-traumatic Stress Disorder (PTSD)</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Stress Disorders, Traumatic</mesh_term>
	<mesh_term>Stress Disorders, Post-Traumatic</mesh_term>
	<mesh_term>Paroxetine</mesh_term>
	<mesh_term>Sertraline</mesh_term>
	<mesh_term>Brexpiprazole</mesh_term>
	<criteria>The patient has PTSD, diagnosed according to DSMIVTR™ and confirmed by the Mini International Neuropsychiatric Interview (MINI). The patient has a ClinicianAdministered PTSD Scale Part 2 (CAPS2) total score ≥70 at Screening and Baseline Visits. The reported duration of the PTSD is at least 3 months. The index traumatic event that led to development of PTSD took place more than 15 years before screening. The patient has a severe personality disorder that in the investigator's opinion may interfere with the conduct of the study. The patient is at significant suicidal risk. Other inclusion and exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>